Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biomarkers for predicting response to tyrosine kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells.

Oncology reports - 1 Feb 2015

Li Jixia, Lin Bihua, Li Xiangyong, Tang Xudong, He Zhiwei, Zhou Keyuan

Abstract excerpt

The epidermal growth factor receptor (EGFR) family is reportedly overexpressed in bladder cancer, and tyrosine kinase inhibitors (TKIs) have been suggested as treatment. Gefitinib (Iressa®) is a selective inhibitor of the EGFR and lapatinib is a dual inhibitor of both the EGFR and HER2 (human EGFR type 2 receptor). Both compounds compete with the binding of ATP to the tyrosine kinase domain of the respective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Triphosphate
Share to Gefitinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lapatinib

Share to Mitogen-Activated Protein Kinase 1

Share to Mitogen-Activated Protein Kinase 3

Share to Quinazolines

Share to Receptor, ErbB-2

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 25482142
DOI: 10.3892/or.2014.3639

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Biomarkers for predicting response to tyrosine kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells.PMID 25482142Read ↗

Emerging therapeutic targets in bladder cancer.Semantic proximity Read ↗

Biomarker-Oriented Therapy in Bladder and Renal Cancer.Semantic proximity Read ↗

[Targeted therapy for locally advanced and/or metastatic bladder cancer].Semantic proximity Read ↗

The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.Semantic proximity Read ↗

Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells.Semantic proximity Read ↗

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.Semantic proximity Read ↗

The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.Semantic proximity Read ↗

Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.Semantic proximity Read ↗

Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profilesSemantic proximity Read ↗

HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer.Semantic proximity Read ↗

Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.